V. Hoff and D. D. , Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, Journal of clinical oncology, vol.15, issue.6, pp.2403-2413, 1997.

T. Conroy and M. D. , FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1825, 2011.
DOI : 10.1056/NEJMoa1011923

URL : https://hal.archives-ouvertes.fr/hal-00598658

C. Tournigand, A. Cervantes, and A. Figer, OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer???A GERCOR Study, Journal of Clinical Oncology, vol.24, issue.3, pp.394-400, 2006.
DOI : 10.1200/JCO.2005.03.0106

M. Koopman, L. Simkens, and A. May, Final results and subgroup analyses of the phase III CAIRO3 study: maintenance treatment with capecitabine + bevacizumab versus observation after induction treatment with chemotherapy + bevacizumab in metastatic colorectal cancer (mCRC), J Clin Oncol, vol.32, issue.3504, p.5, 2014.

T. Cartwright, Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcitabine-based therapy, J Clin Oncol, vol.32, issue.4132, pp.5-2014

J. J. Schulz, Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer, Journal of clinical oncology, vol.20, issue.1, pp.160-164, 2002.

J. P. Neoptolemos, Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer, Journal of clinical oncology, vol.27, issue.33, pp.5513-5518, 2009.

J. V. Cox and J. J. Schulz, Phase II Study of oral capecitabine in patients with advanced or metastatic pancreatic cancer, J Clin Oncol, vol.20, pp.160-164, 2001.

G. Catalano, Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer. Clinical breast cancer, pp.857-860, 2007.

B. T. Hennessy, A. M. Gauthier, L. B. Michaud, G. Hortobagyi, and V. Valero, Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature, Annals of Oncology, vol.16, issue.8, pp.16-1289, 2005.
DOI : 10.1093/annonc/mdi253

G. Giaccone, Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The lancet oncology, pp.521-529, 2010.

M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht et al., Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group, Journal of Clinical Oncology, vol.25, issue.15, pp.25-1960, 2007.
DOI : 10.1200/JCO.2006.07.9525

R. Lopez, M. J. Siegel-r, and . Zou-z, Phase II trial of erlotinib plus capecitabine as first-line treatment for 1, Cancer statistics CA: a cancer journal for clinicians, vol.64, issue.1, pp.9-29, 2014.

J. A. Bray, F. Center, and M. , CA: a cancer journal for clinicians, Global cancer statistics, vol.61, issue.2, pp.69-90, 2011.

G. , J. Ozols, R. Bajorin, and D. , Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening?a report from the, Journal of Clinical Oncology, vol.26, issue.2, pp.313-325, 2008.

C. , T. Desseigne, F. , Y. , and M. , FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, New England Journal of Medicine, vol.364, issue.19, pp.1817-1825, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00598658

P. Fluorouracile, Progression Free Survival OS: Overall Survival MPC: Metastatic Pancreatic Cancer ECOG: Eastern Cooperative Oncology Group PS: Performans Status BMI: Body Mass Index CT: Computerized Tomography TTF: Time to Treatment Failure US: United States QOL: Quality Of Life NSCLC: Non-Squamous Cell Lung Cancer ORR : Objective Response Rate